×
About 576 results

ALLMedicine™ Waldenstrom Macroglobulinemia Center

Research & Reviews  267 results

Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia.
https://doi.org/10.1080/10428194.2020.1832669
Leukemia & Lymphoma; Gunaratne MDSK, Sahakian AJ et. al.

Oct 15th, 2020 - Waldenstrom macroglobulinemia (WM) has an annual incidence of 3-3.2 cases per million-person/year. National Cancer Data Base was used to identify newly diagnosed WM cases requiring initiation of therapy and their annual facility volume was used to...

MYD88 L265P Elicits Mutation-specific Ubiquitination to Drive NF-κB Activation and Lymp...
https://doi.org/10.1182/blood.2020004918
Blood Yu X, Li W et. al.

Oct 7th, 2020 - Myeloid differentiation primary response protein 88 (MYD88) is a critical universal adapter that transduces signaling from the Toll-like receptors and interleukin receptors to downstream NF-kB. MYD88L265P (leucine changed to proline at position 26...

Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibito...
https://doi.org/10.1080/10428194.2020.1775204
Leukemia & Lymphoma; Madamsetty VS, Paulus A et. al.

Jun 19th, 2020 - Targeted drug delivery remains an active area of investigation in hematologic cancers. We have previously reported on a novel nanoparticle formulation (D1X) that can encapsulate drugs within a liposome whose lipid bilayer contains dexamethasone, w...

Catastrophic Antiphospholipid Syndrome as the Initial Presentation of Waldenstrom Macro...
https://doi.org/10.1016/j.clml.2020.05.005
Clinical Lymphoma, Myeloma & Leukemia; Kim D, Thomas A et. al.

Jun 13th, 2020 - Catastrophic Antiphospholipid Syndrome as the Initial Presentation of Waldenstrom Macroglobulinemia.|2020|Kim D,Thomas A,Malinou J,Hardy N,Law JY,|

Clinical Reasoning: Multifocal neuropathies in a patient with Waldenstrom macroglobulin...
https://doi.org/10.1212/WNL.0000000000009741
Neurology Cox BC, Mauermann ML et. al.

Jun 12th, 2020 - Clinical Reasoning: Multifocal neuropathies in a patient with Waldenstrom macroglobulinemia and prior borreliosis.|2020|Cox BC,Mauermann ML,Theel ES,Toledano M,|complications,etiology,complications,

see more →

Guidelines  2 results

Positive Zanubrutinib Data May Spark Change for Treatment of Waldenstrom Macroglobulinemia
https://www.targetedonc.com/view/positive-zanubrutinib-data-may-spark-change-for-treatment-of-waldenstrom-macroglobulinemia

May 28th, 2020 - A higher complete response or very good partial response (CR+VGPR) rate in patients with Waldenström macroglobulinemia (WM) was achieved with Zanubrutinib (Brukinsa), and the drug demonstrated clinically meaningful safety and tolerability, accordi...

Zanubrutinib Shows Efficacy, Tolerability in Waldenstrom Macroglobulinemia
https://www.onclive.com/conference-coverage/asco-2020/zanubrutinib-shows-efficacy-tolerability-in-waldenstrom-macroglobulinemia

May 28th, 2020 - Zanubrutinib (Brukinsa) was associated with a higher complete response or very good partial response (CR+VGPR) rate, as well as clinically meaningful advantages in safety and tolerability, compared with ibrutinib (Imbruvica) in patients with Walde...

see more →

Clinicaltrials.gov  285 results

Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia.
https://doi.org/10.1080/10428194.2020.1832669
Leukemia & Lymphoma; Gunaratne MDSK, Sahakian AJ et. al.

Oct 15th, 2020 - Waldenstrom macroglobulinemia (WM) has an annual incidence of 3-3.2 cases per million-person/year. National Cancer Data Base was used to identify newly diagnosed WM cases requiring initiation of therapy and their annual facility volume was used to...

MYD88 L265P Elicits Mutation-specific Ubiquitination to Drive NF-κB Activation and Lymp...
https://doi.org/10.1182/blood.2020004918
Blood Yu X, Li W et. al.

Oct 7th, 2020 - Myeloid differentiation primary response protein 88 (MYD88) is a critical universal adapter that transduces signaling from the Toll-like receptors and interleukin receptors to downstream NF-kB. MYD88L265P (leucine changed to proline at position 26...

Waldenstrom macroglobulinemia - Care at Mayo Clinic - Mayo Clinic
https://www.mayoclinic.org/diseases-conditions/waldenstrom-macroglobulinemia/care-at-mayo-clinic/mac-20360009

Aug 17th, 2020 - Waldenstrom macroglobulinemia care at Mayo Clinic At Mayo Clinic, a multidisciplinary team of experts works together with you to understand your condition and create a treatment plan that meets your needs and goals. Though this rare disease can't ...

Waldenstrom macroglobulinemia - Diagnosis and treatment - Mayo Clinic
https://www.mayoclinic.org/diseases-conditions/waldenstrom-macroglobulinemia/diagnosis-treatment/drc-20359986

Aug 17th, 2020 - Diagnosis Tests and procedures used to diagnose Waldenstrom macroglobulinemia include: Blood tests. Blood tests may reveal low numbers of healthy blood cells. Also, blood tests are used to detect the IgM proteins produced by the cancer cells. Bloo...

Waldenstrom macroglobulinemia - Symptoms and causes - Mayo Clinic
https://www.mayoclinic.org/diseases-conditions/waldenstrom-macroglobulinemia/symptoms-causes/syc-20359967

Aug 17th, 2020 - We're welcoming patients at Mayo Clinic See our safety precautions in response to COVID-19. Request an appointment. Overview Waldenstrom macroglobulinemia (mak-roe-glob-u-lih-NEE-me-uh) is a rare type of cancer that begins in the white blood cells...

see more →

News  13 results

Positive Zanubrutinib Data May Spark Change for Treatment of Waldenstrom Macroglobulinemia
https://www.targetedonc.com/view/positive-zanubrutinib-data-may-spark-change-for-treatment-of-waldenstrom-macroglobulinemia

May 28th, 2020 - A higher complete response or very good partial response (CR+VGPR) rate in patients with Waldenström macroglobulinemia (WM) was achieved with Zanubrutinib (Brukinsa), and the drug demonstrated clinically meaningful safety and tolerability, accordi...

Zanubrutinib Shows Efficacy, Tolerability in Waldenstrom Macroglobulinemia
https://www.onclive.com/conference-coverage/asco-2020/zanubrutinib-shows-efficacy-tolerability-in-waldenstrom-macroglobulinemia

May 28th, 2020 - Zanubrutinib (Brukinsa) was associated with a higher complete response or very good partial response (CR+VGPR) rate, as well as clinically meaningful advantages in safety and tolerability, compared with ibrutinib (Imbruvica) in patients with Walde...

Change the 'Asymptomatic' Label for Rare Lymphoma Status
https://www.medscape.com/viewarticle/919696

Oct 9th, 2019 - Patients in the early stages of Waldenstrom macroglobulinemia (WM), a rare type of non-Hodgkin lymphoma, are usually followed with observation rather than offered treatment and are labeled "asymptomatic." But this label is inaccurate because many ...

Waldenstrom Macroglobulinemia Clinical Practice Guidelines (2018)
https://reference.medscape.com/viewarticle/905623

Nov 29th, 2018 - The guidelines on the diagnosis, treatment, and follow-up of Waldenstrom macroglobulinemia were released on October 1, 2018, by the European Society for Medical Oncology (ESMO).[1] Diagnosis Waldenstrom macroglobulinemia (WM) is diagnosed based on...

Combo treatment under review for Waldenstrom macroglobulinemia
https://www.mdedge.com/hematologynews/nhlhub/article/168936/indolent-lymphoma/combo-treatment-under-review-waldenstrom
Mary Ellen Schneider

Jun 26th, 2018 - Ibrutinib in combination with rituximab as a treatment for Waldenström macroglobulinemia (WM) is under priority review by the Food and Drug Administration. Ibrutinib, a Bruton’s tyrosine kinase inhibitor, is already approved as a single agent for.

see more →

Patient Education  9 results see all →